Comparison of Ranibizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration treated following a 'Treat and Extend' protocol: efficacy variables from the pre-specified 12-month interim analysis of the RIVAL study

被引：0
|
作者：
Gillies, Mark C. [1 ]
Hunyor, Alex [1 ]
Arnold, Jennifer [2 ]
Pecheur, Francois [3 ]
Underhill, Kathryn [3 ]
Guymer, Robyn H. [4 ]
McAllister, Ian [5 ]
机构：
[1] Univ Sydney, Ophthalmol, Sydney, NSW, Australia
[2] Marsden Eye Specialists, Parramatta, NSW, Australia
[3] Novartis Pharmaceut, Sydney, NSW, Australia
[4] CERA, Sydney, NSW, Australia
[5] Lions Eye Inst, Perth, WA, Australia
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2018年 / 59卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
840
引用
收藏
页数：3
相关论文
共 50 条
  • [1] COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED FOLLOWING A 'TREAT AND EXTEND' PROTOCOL: EFFICACY VARIABLES FROM THE PRE-SPECIFIED 12-MONTH INTERIM ANALYSIS OF THE RIVAL STUDY
    Gillies, Mark C.
    Hunyor, Alex P.
    Arnold, Jennifer J.
    Pecheur, Francois
    Underhill, Kathryn
    Guymer, Robyn H.
    McAllister, Ian L.
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2017, 45 : 29 - 29
  • [2] Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration
    Alaa Din Abdin
    Shady Suffo
    Fatima Asi
    Achim Langenbucher
    Berthold Seitz
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257 : 1671 - 1677
  • [3] Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration
    Abdin, Alaa Din
    Suffo, Shady
    Asi, Fatima
    Langenbucher, Achim
    Seitz, Berthold
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2019, 257 (08) : 1671 - 1677
  • [4] Bimonthly, treat-and-extend and as-needed ranibizumab in naive neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study
    Galvez, Maria Isabel Lopez
    Barquet, Lluis Arias
    Figueroa, Marta S.
    Garcia-Layana, Alfredo
    Moreno, Jose M. Ruiz
    ACTA OPHTHALMOLOGICA, 2020, 98 (07) : E820 - E829
  • [5] Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration
    Alaa Din Abdin
    Asem Mohamed
    Cristian Munteanu
    Isabel Weinstein
    Achim Langenbucher
    Berthold Seitz
    Shady Suffo
    International Journal of Retina and Vitreous, 7
  • [6] Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration
    Abdin, Alaa Din
    Mohamed, Asem
    Munteanu, Cristian
    Weinstein, Isabel
    Langenbucher, Achim
    Seitz, Berthold
    Suffo, Shady
    INTERNATIONAL JOURNAL OF RETINA AND VITREOUS, 2021, 7 (01)
  • [7] Efficacy outcomes and treatment burden of 'as required' ranibizumab to 'Treat and Extend' aflibercept for neovascular Age - related Macular Degeneration: 12 month pre and post switch analysis in clinical practice
    Airody, Archana
    Mankowska, Aleksandra
    Topping, Nicola
    Hanson, Richard
    Walters, Gavin
    Bailey, Fiona
    Gale, Richard
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [8] Efficacy and safety of ranibizumab 0.5 mg treat and extend versus monthly regimen in patients with neovascular age-related macular degeneration: 12-month results from the TREND study.
    Silva, Rufino
    Larsen, Michael
    Feller, Chrystel
    Macfadden, Wayne
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [9] Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol
    Berg, Karina
    Pedersen, Terje R.
    Sandvik, Leiv
    Bragadottir, Ragnheidur
    OPHTHALMOLOGY, 2015, 122 (01) : 146 - 152
  • [10] COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) USING A TREAT-AND-EXTEND REGIMEN: RESULTS OF THE 24-MONTH SECONDARY EFFICACY OUTCOMES FROM THE RIVAL STUDY, A RANDOMIZED CLINICAL TRIAL
    Hunyor, Alex P.
    Arnold, Jennifer J.
    McAllister, Ian L.
    Pecheur, Francois L.
    Heath, Ronelle-Mare
    Guymer, Robyn H.
    Gillies, Marc C.
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2018, 46 : 42 - 42
12345